Kiniksa Pharmaceuticals International, plc
KNSA
$27.65
-$0.09-0.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 481.17M | 423.24M | 384.10M | 338.93M | 301.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 481.17M | 423.24M | 384.10M | 338.93M | 301.77M |
| Cost of Revenue | 219.50M | 189.22M | 149.66M | 126.64M | 105.99M |
| Gross Profit | 261.67M | 234.02M | 234.44M | 212.29M | 195.78M |
| SG&A Expenses | 172.86M | 168.01M | 164.22M | 152.28M | 139.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 496.97M | 468.86M | 410.33M | 366.44M | 332.31M |
| Operating Income | -15.80M | -45.62M | -26.24M | -27.51M | -30.54M |
| Income Before Tax | -6.31M | -36.15M | -16.72M | -18.02M | -21.56M |
| Income Tax Expenses | 10.64M | 7.04M | -7.66M | -7.79M | -30.21M |
| Earnings from Continuing Operations | -16.95 | -43.19 | -9.07 | -10.23 | 8.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.95M | -43.19M | -9.07M | -10.23M | 8.65M |
| EBIT | -15.80M | -45.62M | -26.24M | -27.51M | -30.54M |
| EBITDA | -14.23M | -43.92M | -24.40M | -25.47M | -28.33M |
| EPS Basic | -0.24 | -0.61 | -0.12 | -0.14 | 0.12 |
| Normalized Basic EPS | -0.06 | -0.32 | -0.15 | -0.16 | -0.19 |
| EPS Diluted | -0.25 | -0.61 | -0.14 | -0.16 | 0.11 |
| Normalized Diluted EPS | -0.06 | -0.32 | -0.15 | -0.16 | -0.19 |
| Average Basic Shares Outstanding | 287.70M | 285.68M | 283.74M | 282.20M | 281.11M |
| Average Diluted Shares Outstanding | 291.20M | 285.68M | 286.02M | 284.48M | 285.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |